GSA Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

GSA Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,208	Closed	-$1.22M	–	2074
2023 Q1	$1.22M	Buy	+11,208	New	+$1.24M	0.12%	223
2022 Q4	–	Sell	-9,824	Closed	-$608K	–	2047
2022 Q3	$608K	Buy	9,824 +4,212	+75%	+$294K	0.08%	432
2022 Q2	$448K	Sell	5,612 -3,770	-40%	-$357K	0.07%	567
2022 Q1	$987K	Buy	9,382 +5,059	+117%	+$493K	0.13%	186
2021 Q4	$466K	Buy	4,323 +2,068	+92%	+$226K	0.06%	647
2021 Q3	$247K	Buy	+2,255	New	+$234K	0.03%	1129
2020 Q1	–	Sell	-6,401	Closed	-$232K	–	1791
2019 Q4	$232K	Buy	+6,401	New	+$196K	0.03%	1182
2019 Q3	–	Sell	-10,853	Closed	-$261K	–	1905
2019 Q2	$261K	Sell	10,853 -41,702	-79%	-$1.06M	0.03%	1090
2019 Q1	$1.39M	Sell	52,555 -1,145	-2%	-$27.1K	0.14%	148
2018 Q4	$1.05M	Sell	53,700 -17,400	-24%	-$341K	0.12%	197
2018 Q3	$1.39M	Buy	+71,100	New	+$1.35M	0.08%	463
2017 Q1	–	Sell	-35,920	Closed	-$581K	–	2132
2016 Q4	$581K	Buy	35,920 +17,506	+95%	+$317K	0.03%	898
2016 Q3	$334K	Buy	+18,414	New	+$360K	0.02%	1301
2016 Q2	–	Sell	-16,803	Closed	-$278K	–	2003
2016 Q1	$278K	Sell	16,803 -9,472	-36%	-$166K	0.02%	1338
2015 Q4	$569K	Sell	26,275 -231,831	-90%	-$4.51M	0.03%	1077
2015 Q3	$5.12M	Buy	258,106 +200,969	+352%	+$6.35M	0.25%	43
2015 Q2	$1.99M	Buy	57,137 +27,927	+96%	+$852K	0.08%	378
2015 Q1	$759K	Buy	+29,210	New	+$535K	0.03%	1093
2014 Q1	–	Sell	-34,200	Closed	-$261K	–	1906
2013 Q4	$261K	Buy	+34,200	New	+$184K	0.02%	1312

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's HZNP Position: Q2 2023 in Review

GSA Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 11,208 shares — an estimated $1.22M sold.

GSA Capital Partners first reported a position in HZNP in Q4 2013 and held it in 19 quarters. The position peaked at $5.12M in Q3 2015. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

GSA Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
GSA Capital Partners sold 11,208 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $1.22M.
GSA Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 19 quarters.
GSA Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.12M in Q3 2015.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on GSA Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.